CM 6325
Alternative Names: CM-6325Latest Information Update: 06 Nov 2023
At a glance
- Originator CalciMedica
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Calcium channel antagonists; ORAI1 protein inhibitors; STIM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Pancreatitis; Rheumatoid arthritis
Most Recent Events
- 25 Feb 2021 Preclinical trials in Pancreatitis in USA (PO) (CalciMedica pipeline, February 2021)
- 25 Feb 2021 Preclinical trials in Rheumatoid arthritis in USA (PO) (CalciMedica pipeline, February 2021)
- 25 Feb 2021 CalciMedica announces intention to submit Investigational New Drug application for Rheumatoid Arthritis and Pancreatitis in 2021 (CalciMedica pipeline, February 2021)